NeuroOne Medical Technologies Corp. (NASDAQ: NMTC) completed a 1‑for‑6 reverse stock split of its common shares, consolidating six existing shares into one. The split became effective at 5:00 p.m. Eastern Time on April 15, 2026, and the adjusted shares began trading on a split‑adjusted basis on April 16, 2026. The move was taken to lift the share price above Nasdaq’s $1.00 minimum bid requirement and avoid a potential delisting.
The reverse split was approved by the board and shareholders at the company’s annual meeting on April 3, 2026. Under the new ratio, every six shares will be converted into one share, with fractional shares paid in cash. The company will also adjust the exercise and conversion prices of outstanding options and warrants, while the par value and total equity value remain unchanged.
NeuroOne’s need for a reverse split reflects a prolonged period of share price below the Nasdaq threshold. The company received a 180‑day extension to regain compliance, with a deadline of May 4, 2026. The reverse split is a short‑term measure to maintain listing status while the company continues to pursue growth through its partnership with Zimmer Biomet and the commercialization of its OneRF Trigeminal Nerve Ablation System.
In Q1 Fiscal 2026, NeuroOne reported revenue of $2.9 million, down from $3.3 million in the same quarter a year earlier, and a net loss of $1.4 million, or $0.03 per share. Despite the revenue decline, the company beat analyst expectations for earnings, with EPS of –$0.03 versus a consensus of –$0.04. The beat was driven by disciplined cost management that offset the impact of a lower product mix and the absence of a Zimmer stocking order that had boosted revenue in the prior year.
"The expanded agreement with Zimmer Biomet to include distribution of our OneRF Ablation System is a significant catalyst for the Company. We are confident that the partnership will allow NeuroOne to leverage Zimmer Biomet's leadership position in robotic technology and extensive distribution channel both in the United States and abroad." – Dave Rosa, CEO
"We are projecting fiscal year 2026 sales to be at least $10.5 million, a minimum 17% increase from fiscal year 2025." – Dave Rosa, CEO
Analysts observe that while the reverse split restores Nasdaq compliance, it also signals ongoing challenges in sustaining a share price above the minimum threshold. The company’s market capitalization will remain unchanged, but the consolidation reduces the number of shares outstanding, which may affect liquidity and investor perception. Investors will likely focus on the company’s ability to convert its product revenue growth into profitability and to maintain a share price that meets regulatory requirements.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.